logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hironaga Satake

kochi university
H指数:24
被引数:3,551

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on “Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462”

治疗失败时间作为C-CAT中记录的治疗过程指标。回复关于“肺癌中医疗机构层面的肿瘤学专家可用性与一线治疗失败时间：一项全国性C-CAT登记研究。Curr. Oncol. 2026, 33, 462”的评论

Current Oncology
IF3.4
2026-10-220
OA
Shinya Kajiura; Hironaga Satake; Ryuji Hayashi; Takayuki Yoshino
Gut microbiome features associated with PIK3CA-mutated colorectal cancer: A nationwide pan-cancer genomic and microbial profiling study (MONSTAR-SCREEN)

PIK3CA突变结直肠癌相关的肠道微生物组特征：一项全国性泛癌症基因组学和微生物组学分析研究（MONSTAR-SCREEN）

Scientific Reports
IF3.9
2026-10-040
OAAI
Shogen Boku; Shunsuke A. Sakai; Kentaro Sawada; Satoshi Horasawa; Ayumu Yoshikawa; Yoshiaki Nakamura; Takao Fujisawa; Riu Yamashita; Hironaga Satake; Yoshito Komatsu; Tomohiro Nishina; Manabu Shiozawa; Toshihiro Kudo; Nobuhisa Matsuhashi; Kentaro Yamazaki; Toshifumi Yamaguchi; Hisateru Yasui; Naoki Takahashi; Shigenori Kadowaki; Tadamichi Denda; Takayuki Yoshino
A prospective observational study of treatment sequencing with regorafenib and FTD/TPI in metastatic colorectal cancer: The OSERO study

奥塞罗研究：一项关于regorafenib和FTD/TPI在转移性结直肠癌中治疗顺序的前瞻性观察研究

British Journal of Cancer
IF6.8
2026-09-290
PRE
Takeshi Kawakami; Toshiki Masuishi; Tetsutaro Hamano; Akihiko Chida; Seiichiro Mitani; Hisateru Yasui; Atsushi Ishiguro; Takayuki Ando; Kentaro Sawada; Kazuaki Harada; Naoki Takahashi; Shogen Boku; Tomomi Kashiwada; Taito Esaki; Ayumu Yoshikawa; Keiji Sugiyama; Kouji Yamamoto; Hironaga Satake; Satoshi Yuki; Kentaro Yamazaki; Eiji Oki
Case Report: Discordance between RNA-identified ETV6::RET and clinically reportable DNA profiling in salivary gland secretory carcinoma

病例报告：涎腺分泌性癌中RNA鉴定ETV6::RET与临床可报告的DNA分型之间的不一致

Frontiers in Oncology
IF3.3
2026-09-280
OA
SB Shogen Boku; TF Takao Fujisawa; TS Tomofumi Sakagami; SK Shigenori Kadowaki; HS Hironaga Satake; HY Hisateru Yasui; KO Koushiro Ohtsubo; YS Yasushi Shimizu; TO Tomoyuki Otsuka; BK Bunya Kuze; RY Riu Yamashita; TS Taro Shibuki; YN Yoshiaki Nakamura; HB Hideaki Bando; TY Takayuki Yoshino; MR Milan Radovich; MY Masao Yagi; SO Susumu Okano
Facility-Level Availability of Japanese Society of Medical Oncology Specialists and Recorded First-Line Treatment-Process Duration in Pancreatic Cancer: A Nationwide Center for Cancer Genomics and Advanced Therapeutics Registry Analysis

日本临床肿瘤学会专科医师在机构层面的可用性与记录的胰腺癌一线治疗过程持续时间：一项全国癌症基因组学和先进治疗中心登记分析

Current Oncology
IF3.4
2026-07-020
OAAI
Shinya Kajiura; Hironaga Satake; Naohiko Nakamura; Ryuji Hayashi
Efficacy and safety of peptide radionuclide therapy with 177Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N)

177Lu-DOTATATE肽受体放射性核素治疗在日本晚期神经内分泌肿瘤患者中的疗效与安全性：一项多中心回顾性研究（JON2203-N）

Journal of Gastroenterology
IF5.5
2026-03-230
PRE
Kohei Okamoto; Susumu Hijioka; Noritoshi Kobayashi; Hiroshi Imaoka; Kazuo Hara; Satoshi Takeuchi; Nao Fujimori; Kentaro Sudo; Shigeru Horiguchi; Ryoji Takada; Takashi Ono; Takeshi Terashima; Kazuhiko Shioji; Shunsuke Kondo; Takaaki Furukawa; Masayuki Ueno; Hidetaka Tsumura; Kazutoshi Tobimatsu; Toshifumi Doi; Hiroyuki Asama; Shinya Kawaguchi; Yohei Kitano; Osamu Maeda; Satoshi Kobayashi; Shiho Arima; Michiaki Unno; Eizaburo Ohno; Kazuhito Kawata; Reiko Ashida; Atsushi Naganuma; Go Murohisa; Reiko Yamada; Hironaga Satake; Yuzo Kodama; Isao Yokota; Hiroyuki Okuyama; Satoshi Shimizu; Chigusa Morizane; Makoto Ueno; Hiroaki Nagano; Junji Furuse
A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer

一项关于纳武利尤单抗治疗铂类耐药的复发性或转移性唾液腺癌患者的II期临床试验

JAPANESE JOURNAL OF CLINICAL ONCOLOGY
IF2.2
2025-12-010
OA
Nagatani, Yoshiaki; Kiyota, Naomi; Yamazaki, Tomoko; Asada, Yukinori; Higashino, Masaaki; Satake, Hironaga; Boku, Shogen; Nishimura, Ari; Uemura, Hirokazu; Ota, Ichiro; Yane, Katsunari; Tanaka, Kaoru; Onoe, Takuma; Hirayama, Yuji; Tsujikawa, Takahiro; Fujiwara, Hajime; Shimoda, Hikari; Nibu, Ken-Ichi; Imamura, Yoshinori; Kimbara, Shiro; Koyama, Taiji; Funakoshi, Yohei; Minami, Hironobu
Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab

紫杉类药物联合ramucirumab治疗化疗联合nivolumab后进展的晚期胃癌的疗效与安全性

Scientific Reports
IF3.9
2025-08-070
OA
Toshihiko Matsumoto; Tatsuki Ikoma; Chinatsu Makiyama; Tomoyo Yasuda; Shogen Boku; Akio Nakasya; Nobuhiro Shibata; Hiroki Nagai; Takao Tsuduki; Yusuke Matsumoto; Hisateru Yasui; Reiji Higashi; Akitoshi Sasamoto; Hironaga Satake; Kentaro Inoue; Masashi Kanai; Makoto Yamasaki
A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer

一项二期临床试验，评估在FOLFOXIRI联合贝伐珠单抗失败后，FOLFIRI联合阿柏西普对不可切除性转移性结直肠癌患者的疗效。

international journal of oncology
IF2.8
2025-02-010
PRE
Ando, Koji; Satake, Hironaga; Shimokawa, Mototsugu; Yasui, Hisateru; Negoro, Yuji; Kinjo, Tatsuya; Kizaki, Junya; Baba, Kenji; Orita, Hiroyuki; Hirata, Keiji; Sakamoto, Sanae; Makiyama, Akitaka; Saeki, Hiroshi; Tsuji, Akihito; Baba, Hideo
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors

循环肿瘤DNA分析指导下的晚期消化道肿瘤靶向治疗

NATURE MEDICINE
IF50
2024-09-162
OAAI
Nakamura, Yoshiaki; Ozaki, Hiroshi; Ueno, Makoto; Komatsu, Yoshito; Yuki, Satoshi; Esaki, Taito; Taniguchi, Hiroya; Sunakawa, Yu; Yamaguchi, Kensei; Kato, Ken; Denda, Tadamichi; Nishina, Tomohiro; Takahashi, Naoki; Satoh, Taroh; Yasui, Hisateru; Satake, Hironaga; Oki, Eiji; Kato, Takeshi; Ohta, Takashi; Matsuhashi, Nobuhisa; Goto, Masahiro; Okano, Naohiro; Ohtsubo, Koushiro; Yamazaki, Kentaro; Yamashita, Riu; Iida, Naoko; Yuasa, Mihoko; Bando, Hideaki; Yoshino, Takayuki
QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC

Quattro-ii随机试验: CAPOXIRI bevacizumab与FOLFOXIRI bevacizumab作为mCRC患者的一线治疗

MED
IF11.8
2024-09-010
OA
Bando, Hideaki; Kotani, Daisuke; Satake, Hironaga; Hamaguchi, Tetsuya; Shiozawa, Manabu; Kotaka, Masahito; Masuishi, Toshiki; Yasui, Hisateru; Kagawa, Yoshinori; Komatsu, Yoshito; Oki, Eiji; Yamamoto, Yoshiyuki; Kawakami, Hisato; Misumi, Toshihiro; Taniguchi, Hiroya; Yamazaki, Kentaro; Muro, Kei; Yoshino, Takayuki; Kato, Takeshi; Tsuji, Akihito
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy

与NeoRAS野生型转移性结直肠癌相关的临床特征scrum-japan GOZILA子研究

NATURE COMMUNICATIONS
IF15.7
2024-07-131
OAAI
Osumi, Hiroki; Shinozaki, Eiji; Nakamura, Yoshiaki; Esaki, Taito; Yasui, Hisateru; Taniguchi, Hiroya; Satake, Hironaga; Sunakawa, Yu; Komatsu, Yoshito; Kagawa, Yoshinori; Denda, Tadamichi; Shiozawa, Manabu; Satoh, Taroh; Nishina, Tomohiro; Goto, Masahiro; Takahashi, Naoki; Kato, Takeshi; Bando, Hideaki; Yamaguchi, Kensei; Yoshino, Takayuki

研究方向

暂未获取到该数据
H
Hisateru Yasui
H 指数:25论文数:285被引数:5,540
M
Masahito Kotaka
H 指数:25论文数:239被引数:2,522
A
Akihito Tsuji
H 指数:40论文数:426被引数:1.0万
E
Eiji Oki
H 指数:70论文数:1,185被引数:1.8万
Y
Yu Sunakawa
H 指数:32论文数:478被引数:3,973
S
Shogen Boku
H 指数:10论文数:129被引数:448
T
Takayuki Yoshino
H 指数:88论文数:1,566被引数:5.0万
Y
Yoshinori Kagawa
H 指数:35论文数:632被引数:4,608
W
Wataru Ichikawa
H 指数:33论文数:284被引数:3,624
M
Manabu Shiozawa
H 指数:38论文数:529被引数:6,169